Mobilizing leukemia cells

US11041156B2 · kind B2 · utility

Assignees

• Antisense Therapeutics Ltd · AU
• Children's Hospital Los Angeles · US

Inventors

• George Tachas · Melbourne, AU
• Yong-Mi Kim · Geoje-si, KR

Key dates

• Filing date: May 4, 2018
• Grant date: Jun 22, 2021
• Expiry date: May 4, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method for mobilizing leukemia cells which are α4 integrin positive to the peripheral blood of a human subject, the method comprising administering to the human subject an effective amount of an antisense compound to α4 integrin. The cells may be mobilized from bone marrow. The antisense compound is: 5′-MeCMeUG AGT MeCTG TTT MeUMeCMeC AMeUMeU MeCMeU-3′ wherein, (a) each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester; (b) the nucleotides at the positions 1 to 3 from the 5′ end are 2′-O-(2-methoxyethyl) modified ribonucleosides; (c) the nucleotides at the positions 4 to 12 from the 5′ end are 2′-deoxyribonucleosides; (d) the nucleotides at the positions 13 to 20 from the 5′ end are 2′-O-(2-methoxyethyl) modified ribonucleosides; and (e) all cytosines are 5-methylcytosines (MeC), or a pharmaceutically acceptable salt thereof.